This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma | MicrobiomeTrials
← Back to trials NCT07225621
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-01-28Est. Completion: 2027-12
Enrollment target: 103 participantsLocations Dana Farber Cancer Institute, Boston, Massachusetts, United States Mayo Clinic, Rochester, Minnesota, United States Albany Medical Center, Albany, New York, United States Dent Neurologic Institute, Buffalo, New York, United States Northwell Health, Long Island City, New York, United States New York Langone, New York, New York, United States Columbia University, New York, New York, United States Memorial Sloan Kettering Cancer Center, New York, New York, United States University of Rochester, Rochester, New York, United States Ohio State University, Columbus, Ohio, United States Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States Other microbiome trials you might be interested in Recurrent Glioblastoma Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Relapsed Cancer Recurrent Tumor Glioblastoma Multiforme Recurring Glioblastoma Brain and Central Nervous System Tumors Glioma Glioblastomas Grade IV Astrocytoma GBM Recurrent Glioma (Glioblastoma Multiforme) High Grade Glioma Glioma, Malignant Brain Cancer
Background:
Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. B…
Bethesda, United States Est. completion Dec 31, 2030
Glioblastoma
BKM120 is a newly discovered drug that has been used in other research studies. Information from those other research st…
Los Angeles, United States Completed Oct 2016
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Astrocytoma, Grade III
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of…
Chicago, United States Est. completion Sep 2028